Related Experiment Videos
Is there a role for positive inotropic agents in congestive heart failure: focus on mortality
1Department of Medicine, University of California at San Francisco 94143-0124.
Insights
Congestive heart failure (CHF) treatments vary. Vasodilators help patients with systolic dysfunction, but inotropic therapies show no survival benefit and may harm patients with CHF.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Congestive heart failure (CHF) is a prevalent clinical syndrome with diverse causes.
- Impaired cardiac contractility can precipitate pump failure, leading to significant hemodynamic and neurohormonal changes.
Purpose of the Study:
- To review the mechanism of action of inotropic therapy in CHF.
- To examine clinical trials evaluating inotropic therapy in CHF patients.
Main Methods:
- Literature review of existing clinical trials.
- Analysis of pharmacological mechanisms of inotropic agents.
Main Results:
- Vasodilator therapy is associated with improved symptoms and survival in CHF patients with systolic dysfunction.
- Inotropic therapy has not demonstrated improved survival in CHF and may be associated with worse outcomes.
Conclusions:
- The efficacy and safety of inotropic agents in CHF require careful consideration.
- Treatment strategies for CHF should prioritize therapies with proven survival benefits, such as vasodilators.
Abstract:
Congestive heart failure (CHF) is a common clinical syndrome that may result from a variety of etiologies. Impaired contractility can lead to pump failure and a number of hemodynamic and neurohormonal alterations. Vasodilator therapy improves symptoms and survival in patients with CHF due to systolic dysfunction. Inotropic therapy, on the other hand, has not been shown to improve survival and may even worsen survival. This article reviews the mechanism of action and clinical trials of inotropic therapy in patients with CHF.